As of 2024-12-12, the EV/EBITDA ratio of Eagle Pharmaceuticals Inc (EGRX) is 0.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EGRX's latest enterprise value is 65.84 mil USD. EGRX's TTM EBITDA according to its financial statements is 87.82 mil USD. Dividing these 2 quantities gives us the above EGRX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 16.7x | 13.7x |
| Forward P/E multiples | 17.7x - 29.4x | 25.1x |
| Fair Price | 169.96 - 289.67 | 234.18 |
| Upside | 7842.2% - 13436.1% | 10843.2% |
| Date | EV/EBITDA |
| 2024-12-09 | 0.67 |
| 2024-12-06 | 0.67 |
| 2024-12-05 | 0.68 |
| 2024-12-04 | 0.68 |
| 2024-12-03 | 0.67 |
| 2024-12-02 | 0.67 |
| 2024-11-29 | 0.67 |
| 2024-11-27 | 0.67 |
| 2024-11-26 | 0.68 |
| 2024-11-25 | 0.67 |
| 2024-11-22 | 0.68 |
| 2024-11-21 | 0.68 |
| 2024-11-20 | 0.66 |
| 2024-11-19 | 0.66 |
| 2024-11-18 | 0.68 |
| 2024-11-15 | 0.66 |
| 2024-11-14 | 0.67 |
| 2024-11-13 | 0.67 |
| 2024-11-12 | 0.68 |
| 2024-11-11 | 0.67 |
| 2024-11-08 | 0.67 |
| 2024-11-07 | 0.67 |
| 2024-11-06 | 0.67 |
| 2024-11-05 | 0.67 |
| 2024-11-04 | 0.65 |
| 2024-11-01 | 0.66 |
| 2024-10-31 | 0.66 |
| 2024-10-30 | 0.65 |
| 2024-10-29 | 0.65 |
| 2024-10-28 | 0.64 |
| 2024-10-25 | 0.66 |
| 2024-10-24 | 0.66 |
| 2024-10-23 | 0.66 |
| 2024-10-22 | 0.67 |
| 2024-10-21 | 0.67 |
| 2024-10-18 | 0.68 |
| 2024-10-17 | 0.66 |
| 2024-10-16 | 0.67 |
| 2024-10-15 | 0.66 |
| 2024-10-14 | 0.66 |
| 2024-10-11 | 0.68 |
| 2024-10-10 | 0.66 |
| 2024-10-09 | 0.68 |
| 2024-10-08 | 0.66 |
| 2024-10-07 | 0.66 |
| 2024-10-04 | 0.68 |
| 2024-10-03 | 0.74 |
| 2024-10-02 | 0.75 |
| 2024-10-01 | 0.83 |
| 2024-09-30 | 0.84 |